Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
Shukla Sath
CEO & President at Spero Therapeutics. Filing since 29 Aug 2022.
CIK 0001782817
Company
Date
Role
Action
Shares
Amount
Of holding
SPRO
Spero Therapeutics, Inc.
5 Feb 2025
CEO & President
Sold at will
155,333
$121.16K
8.2%
SPRO
Spero Therapeutics, Inc.
27 Aug 2024
CEO & President
Sold at will
2,757
$3.72K
0.2%
SPRO
Spero Therapeutics, Inc.
5 Aug 2024
CEO and President
Sold at will
17,641
$23.11K
1.5%
SPRO
Spero Therapeutics, Inc.
2 Aug 2024
CEO and President
Sold at will
14,800
$19.54K
1.3%
SPRO
Spero Therapeutics, Inc.
5 Feb 2024
CEO and President
Sold on a plan
45,093
$65.38K
3.7%
SPRO
Spero Therapeutics, Inc.
2 Feb 2024
CEO and President
Sold on a plan
30,901
$42.33K
2.5%
SPRO
Spero Therapeutics, Inc.
29 Aug 2023
CEO and President
Sold on a plan
4,163
$5.41K
0.7%
SPRO
Spero Therapeutics, Inc.
28 Aug 2023
CEO and President
Sold on a plan
1,854
$2.34K
0.3%
SPRO
Spero Therapeutics, Inc.
2 Feb 2023
Chief Financial Officer
Sold, plan not stated
9,504
$17.37K
3.0%
SPRO
Spero Therapeutics, Inc.
29 Aug 2022
Chief Financial Officer
Sold, plan not stated
6,017
$5.38K
9.7%
10 decisions on file.
